IP Verse

Tumor-Treating Pharmaceutical Composition - EP3581183

The patent EP3581183 was granted to Eisai R&D Management on Nov 29, 2023. The application was originally filed on Feb 6, 2018 under application number EP18751614A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3581183

EISAI R&D MANAGEMENT
Application Number
EP18751614A
Filing Date
Feb 6, 2018
Status
Granted And Under Opposition
Oct 27, 2023
Grant Date
Nov 29, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STADA ARZNEIMITTELAug 29, 2024HAMM & WITTKOPPADMISSIBLE

Patent Citations (20) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2004253205
DESCRIPTIONUS2004259834
DESCRIPTIONUS2009209580
DESCRIPTIONUS2009264464
DESCRIPTIONUS2010105031
DESCRIPTIONUS6217866
DESCRIPTIONUS7253286
DESCRIPTIONUS9174998
DESCRIPTIONWO2009140549
INTERNATIONAL-SEARCH-REPORTJP2016528162
INTERNATIONAL-SEARCH-REPORTWO2015098853
INTERNATIONAL-SEARCH-REPORTWO2016204193
INTERNATIONAL-SEARCH-REPORTWO2016208576
OPPOSITIONUS2015005343
OPPOSITIONUS2015175615
OPPOSITIONWO2015144934
OPPOSITIONWO2016208576
SEARCHUS2015005343
SEARCHUS2015175615
SEARCHWO2016208576

Non-Patent Literature (NPL) Citations (7) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- D9 - Lenvima (no date to be found)-
OPPOSITION- David Tai , Keith Wells , John Arcaroli , Chad Vanderbilt , Dara L Aisner , Wells A Messersmith , Christopher H Lieu, "Targeting the WNT Signaling Pathway in Cancer Therapeutics.", The Oncologist, AlphaMed Press, Inc., United States, United States , (20151001), vol. 20, no. 10, doi:10.1634/theoncologist.2015-0057, ISSN 1549-490X, pages 1189 - 1198, XP002777682-
OPPOSITION- Molina Ana M.; Hutson Thomas E.; Larkin James; Gold Anne M.; Wood Karen; Carter Dave; Motzer Robert; Michaelson M. Dror, "A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)", Cancer chemotherapy and pharmacology,, DE , (20131105), vol. 73, no. 1, doi:10.1007/s00280-013-2339-y, ISSN 0344-5704, pages 181 - 189, XP035339586
OPPOSITION- Olivieri A., Manzione L., "Dasatinib: a new step in molecular target therapy", Annals of Oncology, (20070601), vol. 18, doi:10.1093/annonc/mdm223, ISSN 0923-7534, pages vi42 - vi46, XP093211433
OPPOSITION- Padma Viswanadha Vijaya, "An overview of targeted cancer therapy", BioMedicine, (20151201), vol. 5, no. 4, doi:10.7603/s40681-015-0019-4, ISSN 2211-8039, pages 1 - 6, XP093211434
SEARCH- MOLINA ANA M ET AL, "A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 73, no. 1, doi:10.1007/S00280-013-2339-Y, ISSN 0344-5704, (20131105), pages 181 - 189, (20131105), XP035339586 [A] 1-10 * discussion *
SEARCH- EMAMI K H ET AL, "A small molecule inhibitor of beta-catenin/cyclic AMP response element-binding protein transcription", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, (20040824), vol. 101, no. 34, doi:10.1073/PNAS.0404875101, ISSN 0027-8424, pages 12682 - 12687, XP002317529 [A] 1-10 * discussion *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents